Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease (Q38086611)

28 August 2017

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease (English)

1 reference

28 August 2017

1 reference

André J Scheen

1

1 reference

PubMed ID

23461781

28 August 2017

language of work or name

English

0 references

publication date

6 March 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

1 reference

28 August 2017

9

1 reference

28 August 2017

529-550

1 reference

28 August 2017

5

1 reference

28 August 2017

Leptin and renal disease

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Temporal trends in the prevalence of diabetic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Selection and dosing of medications for management of diabetes in patients with advanced kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Management of glycemia in patients with diabetes mellitus and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Limitations and future treatment options in type 2 diabetes with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Management of diabetes in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Medications in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Oral antidiabetic agents. A guide to selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacologic management of the older patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Estimation of renal function in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Lactic acidosis in biguanide-treated diabetics: a review of 330 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Lactic acidosis induced by metformin: incidence, management and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Contraindications can damage your health--is metformin a case in point?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical pharmacokinetics of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical Pharmacokinetics of Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Disposition of metformin (N,N-dimethylbiguanide) in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Measurement of the renal clearance of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Kidney function and age are both predictors of pharmacokinetics of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Metformin therapy in patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

A risk-benefit assessment of metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Metformin use in renal dysfunction: is a serum creatinine threshold appropriate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Limitations of metformin use in patients with kidney disease: are they warranted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Renal status among patients using metformin in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Metformin use and mortality among patients with diabetes and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Review: metformin: potential benefits and use in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Metformin in patients with chronic kidney disease: strengths and weaknesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Drug-induced hypoglycaemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Frequency of hypoglycemia and its significance in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Rates of hypoglycemia in users of sulfonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Intervention to decrease glyburide use in elderly patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Repaglinide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of nateglinide in renally impaired diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Peroxisome proliferator-activated receptor gamma agonists in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The safety of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Rosiglitazone is associated with mortality in chronic hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The pharmacokinetics of pioglitazone in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Outcomes and lessons from the PROactive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of rosiglitazone in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Efficacy and safety of Jentadueto® (linagliptin plus metformin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Exenatide-associated ischemic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Mild renal impairment and the efficacy and safety of liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

The renal metabolism of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Gliclazide modified release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.777428

10.1517/17425255.2013.777428

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23461781